Idronoxil (Phenoxodiol): A Comprehensive Monograph on a Multi-Modal Signal Transduction Inhibitor and Immuno-Oncology Agent

Executive Summary

Idronoxil, also known as Phenoxodiol, is an investigational small molecule anticancer agent with a compelling and multifaceted mechanism of action. As a synthetic isoflavone analog of the naturally occurring compound genistein, Idronoxil represents a class of drugs known as multiple signal transduction regulators. Its developmental trajectory provides a salient case study in pharmaceutical science, illustrating a journey from a highly promising but pharmacokinetically flawed molecule to its revitalization through advanced formulation science. The Australian company Noxopharm Ltd. has reformulated Idronoxil into Veyonda® (NOX66), a proprietary rectal suppository designed to overcome the rapid metabolic inactivation that halted its initial clinical development.

The primary pharmacological activity of Idronoxil is the re-engagement of apoptosis (programmed cell death) in cancer cells. It achieves this through a multi-pronged attack on key cellular survival pathways. Its proposed primary target is the Ecto-NOX disulfide-thiol exchanger 2 (ENOX2), a cancer-specific cell surface enzyme. Inhibition of ENOX2 disrupts downstream signaling, leading to the degradation of critical anti-apoptotic proteins such as X-linked inhibitor of apoptosis (XIAP) and FLICE-inhibitory protein (FLIP), thereby activating both the intrinsic and extrinsic caspase cascades. Concurrently, Idronoxil functions as a DNA topoisomerase II inhibitor and induces p53-independent cell cycle arrest, broadening its cytotoxic and cytostatic effects.

More recently, Idronoxil has emerged as a novel immuno-oncology agent. Preclinical and clinical data indicate it can modulate both innate and adaptive immune responses. A key aspect of this activity is its hypothesized ability to convert immunologically "cold" tumors, which are devoid of immune cells and resistant to immunotherapy, into "hot" tumors that are infiltrated by T-cells and susceptible to immune attack. This provides a strong rationale for its combination with immune checkpoint inhibitors. Furthermore, Idronoxil exhibits potent anti-inflammatory properties, suggesting a unique dual capacity to stimulate targeted anti-tumor immunity while potentially mitigating systemic pathological inflammation.

Clinically, the Veyonda® formulation has demonstrated a favorable safety profile and encouraging efficacy signals in late-stage, heavily pre-treated cancer patient populations. In metastatic castration-resistant prostate cancer (mCRPC), it has shown promise as both a radio-sensitizer in combination with external beam radiation (DARRT trial) and as a synergistic partner for radionuclide therapy (LuPIN trial). Its potential as a chemo-sensitizer has been explored in refractory solid tumors (CEP trial).

While Idronoxil remains an investigational agent without marketing approval from major regulatory bodies like the FDA, EMA, or TGA, it has received Orphan Drug Designation from the FDA for soft tissue sarcoma. Its future hinges on the successful completion of larger, pivotal clinical trials to confirm the promising results seen in early-to-mid-stage studies. Idronoxil represents a "second-chance" drug whose full therapeutic potential, particularly as a cornerstone of combination therapies in the modern oncology landscape, may now be realized through a deeper understanding of its immunomodulatory effects and the successful circumvention of its historical pharmacokinetic limitations.

1.0 Introduction and Drug Classification

1.1 Overview of Idronoxil as an Investigational Anticancer Agent

Idronoxil is a small molecule drug that has been the subject of extensive investigation as a potential treatment for cancer for more than two decades.[1] It belongs to the therapeutic category of signal transduction inhibitors, a class of targeted therapies designed to interfere with the complex molecular communication networks that drive cancer cell growth, proliferation, and survival.[3] The developmental history of Idronoxil is a notable narrative within oncology research. The molecule demonstrated potent and multifaceted biological activity in preclinical models, but its progression into later-stage clinical use was historically impeded by significant formulation and bioavailability challenges. A central theme in its modern development is the strategic effort to overcome these pharmacokinetic hurdles, which has led to its re-emergence as a promising clinical candidate.[1]

The scientific and clinical journey of Idronoxil mirrors the broader evolution of oncology drug development itself. It began with a scaffold inspired by natural products, progressed to a targeted therapy based on an understanding of molecular pathways, and has now entered the modern era of immuno-oncology. This progression highlights the critical importance of advanced formulation science in unlocking the full potential of a pharmacologically active but pharmacokinetically challenged molecule.

1.2 Chemical Lineage: A Synthetic Isoflavone Analog of Genistein

Idronoxil's chemical origins trace back to genistein, a naturally occurring isoflavone found in plants such as soybeans.[6] The development of isoflavone-based anticancer agents was initially spurred by epidemiological observations suggesting an inverse relationship between the dietary intake of these compounds and the incidence of certain cancers.[10] This provided a strong rationale for the synthesis of novel analogs with enhanced potency and improved drug-like properties.

Idronoxil, also widely known in the scientific literature as Phenoxodiol, is a synthetic derivative of genistein. Through targeted chemical modifications, researchers designed Idronoxil to possess significantly increased anticancer activity compared to its parent compound, without a corresponding increase in toxicity.[10] This strategic molecular engineering aimed to harness the beneficial biological properties of the isoflavone scaffold while optimizing it for therapeutic application in oncology.

1.3 Therapeutic Class: Signal Transduction and ENOX2 Inhibitor

Idronoxil is formally classified as an investigational signal transduction inhibitor.[3] More specifically, it is described as a "multiple signal transduction regulator" (MSTR), a term that reflects its capacity to simultaneously modulate a number of dysregulated pro-survival pathways within cancer cells.[13] This polypharmacological profile is a key feature of its mechanism of action.

A more precise classification identifies Idronoxil as an inhibitor of the tumor-associated NADH oxidase, Ecto-NOX disulfide-thiol exchanger 2 (ENOX2).[3] The expression of the ENOX2 oncogene is largely restricted to cancer cells, making it a highly selective target and providing a potential therapeutic window that minimizes effects on normal, healthy tissues.[16] This dual classification as both a broad signal transduction regulator and a specific ENOX2 inhibitor encapsulates the multifaceted nature of its anticancer activity.

2.0 Chemical Identity and Physicochemical Properties

A precise understanding of Idronoxil's chemical identity and physical properties is fundamental to interpreting its pharmacology, formulation history, and therapeutic potential.

2.1 Nomenclature and Identification Codes

To ensure clarity and facilitate cross-referencing across scientific literature and regulatory databases, the molecule is identified by a variety of names and codes:

• Generic and Official Names: The internationally recognized names are Idronoxil, with regional variations such as Idronoxilo and Idronoxilum.[4]
• Common Synonyms: In much of the preclinical and early clinical literature, it is referred to as Phenoxodiol. Other common synonyms include Dehydroequol and Haginin E.[4]
• Developmental and Formulation Codes: Developmental codes include NV-06. The modern suppository formulation developed by Noxopharm is designated NOX66 and branded as Veyonda®.[4]
• Systematic (IUPAC) Names: The formal chemical names are 3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol and 3-(4-Hydroxyphenyl)-2H-chromen-7-ol.[4]
• Database Identifiers: It is cataloged in major chemical and drug databases, including DrugBank (DB04915), Chemical Abstracts Service (CAS Number: 81267-65-4), PubChem Compound ID (219100), FDA UNII (995FT1W541), and ChEMBL (CHEMBL1957038).[3]

2.2 Molecular Structure and Formula

The molecular composition and structure of Idronoxil are definitively characterized as follows:

• Molecular Formula: $C_{15}H_{12}O_{3}$.[4]
• Molecular Weight: 240.25 g/mol.[4]
• Structural Identifiers: The molecule's two-dimensional structure is unambiguously represented by standard chemical informatics codes, including InChI, InChIKey, and SMILES.[4] The molecule is achiral, meaning it does not have a non-superimposable mirror image.[19]

2.3 Physical and Chemical Characteristics

The physicochemical properties of Idronoxil have significant implications for its formulation and biological activity:

• Appearance: It is described as a solid powder, with a color ranging from white to off-white or light brown.[21]
• Solubility: A critical property of Idronoxil is its poor aqueous solubility. It is reported to be soluble in organic solvents like dimethyl sulfoxide (DMSO) but is not soluble in water.[21] This lipophilic nature is a primary driver of the formulation and bioavailability challenges that have defined its development history. Poor water solubility can lead to inefficient absorption from the gastrointestinal tract for oral formulations and necessitates complex excipients for intravenous delivery, directly foreshadowing the pharmacokinetic issues that were later observed.
• Stability and Storage: The compound is chemically stable, with a reported shelf life of at least 4 years when stored properly.[6] The recommended storage conditions are dry, dark, and at refrigerated (0-4 °C) or frozen (-20 °C) temperatures for short-term and long-term storage, respectively. It is sufficiently stable to be shipped at ambient temperatures.[21]

Table 1: Chemical and Physical Properties of Idronoxil

Property	Value	Source(s)
Generic Name	Idronoxil	19
Common Synonyms	Phenoxodiol, Dehydroequol, Haginin E	6
DrugBank ID	DB04915	3
CAS Number	81267-65-4	6
PubChem CID	219100	4
Molecular Formula	$C_{15}H_{12}O_{3}$	19
Molecular Weight	240.25 g/mol	19
IUPAC Name	3-(4-hydroxyphenyl)-2H-chromen-7-ol	4
SMILES	C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O	4
InChIKey	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	19
Appearance	White to light brown powder	21
Solubility	Soluble in DMSO; not soluble in water	21
Stability	Stable for $\geq$ 4 years under proper storage	6

3.0 Comprehensive Pharmacological Profile

Idronoxil exhibits a complex and multifaceted pharmacological profile, acting on multiple, distinct cellular targets and pathways to exert its anticancer effects. This polypharmacology is a defining characteristic, suggesting an innate capacity to counteract the redundant survival mechanisms often employed by cancer cells.

3.1 Primary Mechanism of Action: Re-engagement of Apoptotic Pathways

The core anticancer mechanism of Idronoxil is its ability to restore the process of programmed cell death, or apoptosis, in malignant cells. Cancer cells are characterized by their ability to evade apoptosis by upregulating various survival signals. Idronoxil systematically dismantles this pro-survival machinery.[13]

3.1.1 Inhibition of the Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2)

A primary and highly specific molecular target of Idronoxil is ENOX2, also known as tumor-associated NADH oxidase (tNOX).[3] ENOX2 is a cell surface enzyme whose expression is largely restricted to cancer cells, making it an attractive therapeutic target.[16] It plays a crucial role in cell growth and is believed to help maintain high levels of anti-apoptotic proteins within the cancer cell.[9] By binding to and inhibiting the function of ENOX2, Idronoxil effectively "switches off" a key source of pro-survival signaling, initiating a cascade of events that leads to apoptosis.[15]

3.1.2 Degradation of Anti-Apoptotic Proteins: XIAP and FLIP

A direct and critical consequence of Idronoxil's activity is the disruption and subsequent degradation of key intracellular proteins that function as brakes on the apoptotic process.

• X-linked inhibitor of apoptosis (XIAP): XIAP is a potent endogenous inhibitor of apoptosis that directly binds to and inactivates caspases, the primary executioner enzymes of cell death. Idronoxil has been consistently shown to inhibit XIAP and promote its degradation.[3] By removing this critical inhibitor, Idronoxil effectively releases the brakes on the caspase cascade, allowing apoptosis to proceed.
• FLICE-inhibitory protein (FLIP): FLIP is a key inhibitor of the extrinsic, or death receptor-mediated, pathway of apoptosis. It functions by preventing the activation of pro-caspase-8. Idronoxil disrupts the expression of FLIP, thereby sensitizing cancer cells to death signals originating from the cell surface.[4]

3.1.3 Activation of the Intrinsic and Extrinsic Caspase Cascades

By systematically removing the XIAP and FLIP inhibitors, Idronoxil triggers both of the major apoptotic signaling pathways, creating a robust, multi-pronged pro-death signal.

• Extrinsic (Death Receptor) Pathway: The degradation of FLIP allows death receptor signaling (e.g., via the Fas receptor) to successfully activate caspase-8, initiating the extrinsic apoptotic cascade. This is clinically relevant, as Idronoxil has been shown to restore sensitivity to Fas-mediated apoptosis in previously resistant cancer cells.[6]
• Intrinsic (Mitochondrial) Pathway: Idronoxil activates the mitochondrial caspase system, a central hub of apoptosis regulation.[7] This leads to mitochondrial depolarization and the release of pro-apoptotic factors into the cytoplasm, including cytochrome c and Smac/Diablo. Smac/Diablo further contributes to apoptosis by binding to and sequestering any remaining XIAP, fully unleashing the activity of caspase-9 and the downstream executioner caspase-3.[13]

The ability of Idronoxil to attack multiple, semi-independent targets and pathways simultaneously suggests a pre-programmed ability to combat therapeutic resistance. A cancer cell can often evade a single-target agent by upregulating an alternative survival pathway. However, to survive the multi-pronged assault of Idronoxil, a cell would need to develop several distinct resistance mechanisms concurrently, a far more challenging biological feat. This inherent polypharmacology provides a strong mechanistic basis for the potent chemosensitizing effects observed in clinical studies.[9]

3.2 Secondary Mechanisms of Action

In addition to its primary role as an apoptosis inducer, Idronoxil possesses other distinct anticancer activities that contribute to its overall efficacy.

3.2.1 Inhibition of DNA Topoisomerase II

Idronoxil also functions as a DNA topoisomerase II inhibitor. It acts by stabilizing the "cleavable complex," an intermediate in the enzyme's reaction cycle where the DNA is cut. This stabilization prevents the re-ligation of the DNA strands, leading to the accumulation of double-strand breaks and catastrophic DNA damage, which ultimately triggers cell death.[7] This mechanism is shared with several well-established chemotherapeutic agents, such as etoposide and doxorubicin.

3.2.2 Induction of G1/S Phase Cell Cycle Arrest via p21WAF1

Preclinical studies have demonstrated that Idronoxil can halt the proliferation of cancer cells by inducing cell cycle arrest at the G1/S checkpoint.[7] This arrest is mediated by the upregulation of the p21WAF1 protein, a potent cyclin-dependent kinase inhibitor that acts as a gatekeeper for cell cycle progression. A critically important feature of this mechanism is that it occurs in a p53-independent manner.[7] The p53 tumor suppressor gene is the most frequently mutated gene in human cancers, and its inactivation is a major cause of resistance to many DNA-damaging therapies that rely on functional p53 to induce cell cycle arrest or apoptosis. By bypassing the need for p53, Idronoxil has the potential to be effective in a broad range of highly refractory, p53-mutant tumors, which represent a significant clinical challenge.

3.3 Modulation of Pro-Survival Signaling Pathways (Akt, S1P, Ceramide)

Idronoxil further disrupts cancer cell survival by modulating key signaling lipids and protein kinases.

• Akt Pathway: Idronoxil has been shown to downregulate both the phosphorylation (activation) and total expression of Akt, a central protein kinase in pathways that promote cell survival, proliferation, and growth.[13] The inhibition of Akt signaling is mechanistically linked to the subsequent degradation of XIAP.[13]
• Sphingolipid Rheostat: The drug modulates the critical balance between the pro-survival lipid sphingosine-1-phosphate (S1P) and the pro-apoptotic lipid ceramide. Idronoxil inhibits the production of S1P and promotes the accumulation of ceramide.[9] This shift in the sphingolipid rheostat away from survival and towards death is a key consequence of ENOX2 inhibition and a major contributor to its pro-apoptotic effects.

3.4 Anti-Angiogenic Activity

Beyond its direct effects on cancer cells, Idronoxil has also been shown to possess anti-angiogenic properties.[13] Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. By inhibiting this process, Idronoxil can further contribute to the control of tumor progression by limiting the tumor's access to oxygen and nutrients.

4.0 Immunomodulatory Functions and Therapeutic Potential

A paradigm shift in the understanding of Idronoxil has occurred in recent years, with a growing body of evidence revealing its function not just as a direct anticancer agent but also as a potent modulator of the tumor immune microenvironment. This dual functionality positions it as a highly promising candidate for the modern era of cancer immunotherapy.

4.1 From Anti-Cancer to Immuno-Oncology: A Mechanistic Shift

The initial recognition of Idronoxil's immunomodulatory potential stemmed from clinical observations. In early trials combining the Veyonda® formulation with radiotherapy, investigators noted abscopal responses—the shrinkage of tumors located outside the field of radiation.[15] Such effects are a hallmark of a systemic, tumor-specific immune response, prompting a dedicated research program to elucidate the underlying immunological mechanisms of Idronoxil's action.

4.2 Activation of Innate and Adaptive Immune Responses

Subsequent preclinical research has confirmed that Idronoxil activates key cellular players from both the innate and adaptive arms of the immune system.[15] Laboratory studies using human immune cells have shown that Idronoxil can increase the numbers and functional activity of Natural Killer (NK) cells, which are part of the innate immune system's first line of defense against tumors. Furthermore, it activates adaptive immune cells, including CD4+ (T-helper) and CD8+ (cytotoxic) T-lymphocytes, causing them to proliferate and cluster in preparation for an anti-tumor attack.[15]

4.3 The "COLD-to-HOT" Tumor Conversion Hypothesis and Synergy with Checkpoint Inhibitors

One of the most significant challenges in immuno-oncology is that many tumors are immunologically "cold"—they lack a pre-existing immune cell infiltrate and are therefore invisible to the immune system and unresponsive to immune checkpoint inhibitors (ICIs) such as anti-PD-1 or anti-PD-L1 antibodies.[15] A major goal in the field is to find agents that can convert these "cold" tumors into "hot," immune-infiltrated tumors.

Idronoxil has emerged as a leading candidate to achieve this goal. Preclinical studies using tumor spheroid models, which mimic small micro-tumors, have demonstrated that Idronoxil enables activated T-cells to infiltrate the tumor clusters, leading to cancer cell killing.[32] This "cold-to-hot" conversion provides a powerful mechanistic rationale for combining Idronoxil with ICIs. The hypothesis is that Idronoxil can prime the tumor microenvironment, allowing the ICIs to then unleash the full cytotoxic potential of the newly infiltrated T-cells. This strategy could dramatically expand the efficacy of ICIs to a much broader range of cancer types and patients who currently derive little to no benefit.[15] The mechanism for this effect is thought to be linked, at least in part, to Idronoxil's inhibition of S1P, a signaling molecule known to promote tumor resistance to immune cell infiltration.[23]

4.4 Anti-Inflammatory Properties and Cytokine Storm Mitigation

In a seemingly paradoxical but therapeutically valuable manner, Idronoxil also possesses potent anti-inflammatory properties. Research has shown that it can block the production of a range of pro-inflammatory cytokines, including the pivotal cytokine Interleukin-6 (IL-6).[37] The mechanism may involve the suppression of STING-mediated inflammatory pathways.[34]

This dual immunomodulatory profile—simultaneously activating targeted anti-tumor immunity while suppressing systemic, pathological inflammation—is a rare and highly desirable characteristic. Standard immunotherapies often work by inducing inflammation, which can lead to severe systemic immune-related adverse events (irAEs). Idronoxil appears to rebalance the immune system in a more nuanced way, promoting the beneficial anti-tumor response while potentially tamping down the detrimental systemic inflammation. This suggests that in combination with an ICI, Idronoxil could not only enhance efficacy by turning tumors "hot" but also improve the safety profile by mitigating the risk of severe cytokine-driven irAEs. This unique profile led to the exploration of an oral formulation, NOX-19, for its potential to treat hyper-inflammatory conditions like the cytokine storm associated with severe viral infections or sepsis.[37]

5.0 Preclinical Efficacy and Proof-of-Concept

The clinical development of Idronoxil is built upon a robust foundation of preclinical studies that have established its anticancer activity and provided initial proof-of-concept across a wide range of malignancies.

5.1 In Vitro Cytotoxicity and Mechanistic Studies Across Malignancies

In laboratory settings, Idronoxil has consistently demonstrated potent anticancer activity against a diverse array of human cancer cell lines. These include models of ovarian, prostate, colorectal, melanoma, cervical, and renal cancers, as well as hematological malignancies like leukemia.[6]

A particularly significant finding from these in vitro studies is the apparent tumor selectivity of the drug. In one key study, Idronoxil effectively reduced the viability of primary chemoresistant ovarian cancer cells while having minimal effect on non-cancerous ovarian surface epithelial cells at the same concentration.[6] This suggests a therapeutic window where the drug preferentially targets malignant cells. Across various models, Idronoxil has been shown to inhibit colony formation, a measure of a cell's ability to proliferate indefinitely, and to robustly induce apoptosis.[6]

5.2 In Vivo Efficacy in Animal Models of Cancer

The promising in vitro results have been successfully translated into animal models of cancer, confirming the drug's activity in a more complex biological system.

• In a chemically induced model of mammary carcinogenesis in rats, treatment with Idronoxil led to a significant increase in the latency to tumor formation and a reduction in the total number of tumors that developed, demonstrating a cancer-preventative effect.[6]
• In therapeutic models using human cancer cell xenografts in immunocompromised mice, oral administration of Idronoxil resulted in considerable inhibition of tumor growth. This was specifically demonstrated in a model using LNCaP prostate cancer cells.[11]

An intriguing and mechanistically informative observation emerged from one in vivo study, where a lower dose of Idronoxil (10 mg/kg) was found to be more effective at restricting tumor size and improving overall survival than a higher dose (20 mg/kg).[21] This non-linear dose-response relationship is counterintuitive for a conventional cytotoxic agent, where higher doses typically yield greater efficacy. This finding strongly suggests that Idronoxil's primary in vivo mechanism is not simple, dose-dependent cell killing, but rather a more complex biological modulation. This observation aligns perfectly with the immunomodulatory hypothesis, as immune responses often follow a bell-shaped curve where an optimal level of stimulation is most effective, and excessive stimulation can lead to T-cell exhaustion or anergy. This preclinical result provides compelling early evidence that the immunomodulatory function of Idronoxil is a critical component of its overall anticancer effect in vivo.

6.0 Clinical Development and Trial Analysis

The clinical development of Idronoxil has been a long and complex journey, defined by the challenge of translating its potent biological activity into a clinically viable therapeutic. The evolution of its formulation is central to this story, enabling the current wave of promising clinical trials.

6.1 The Developmental Challenge: Overcoming Poor Bioavailability

Despite the strong preclinical rationale, the initial clinical development of Idronoxil was ultimately discontinued. The primary obstacle was its extremely poor bioavailability in humans, observed with both oral and intravenous formulations.[1] The molecule was found to be highly susceptible to rapid and extensive Phase 2 metabolism, primarily through glucuronidation. This process attaches a large, water-soluble sugar moiety to the drug, which inactivates it and facilitates its rapid elimination from the body.[5] Consequently, early formulations failed to maintain a sufficient concentration of the active, non-metabolized drug in the bloodstream to achieve a sustained therapeutic effect.

6.2 Veyonda® (NOX66): A Formulation to Enhance Pharmacokinetic Performance

The Australian biotechnology company Noxopharm was established with the primary goal of solving this critical bioavailability problem and revitalizing the Idronoxil program.[2] Their key innovation is Veyonda® (development code NOX66), a novel dosage formulation of Idronoxil as a rectal suppository.[5]

This route of administration was specifically chosen to bypass the hepatic first-pass effect. When a drug is absorbed through the rectal mucosa, a significant portion of the venous drainage bypasses the liver and enters the systemic circulation directly. This allows the drug to avoid the high concentration of Phase 2 metabolic enzymes in the liver that were responsible for its rapid inactivation. The explicit purpose of the Veyonda® formulation is to ensure that a much higher percentage of the administered dose reaches the bloodstream in its bioactive, non-metabolized form, thereby overcoming the fundamental limitation of all previous formulations.[5] The positive clinical results from recent trials strongly suggest that this formulation strategy has been successful.

6.3 Analysis of Key Clinical Programs

The Veyonda® formulation has enabled a multi-pronged clinical development strategy focused on leveraging Idronoxil's potential as a combination therapy in areas of high unmet medical need.

6.3.1 Prostate Cancer: The DARRT and LuPIN Combination Trials

Metastatic castration-resistant prostate cancer (mCRPC) is the most advanced and well-studied indication for Veyonda®.

• DARRT (Direct and Abscopal Response to Radiotherapy): This program investigates Veyonda® as a radio-sensitizer. The Phase Ib DARRT-1 trial (NCT03307629) combined Veyonda® with a short course of low-dose, palliative external beam radiation in men with late-stage mCRPC. The results showed that the combination was safe and well-tolerated. More importantly, it produced promising signals of durable efficacy, with a high proportion of patients achieving significant PSA reductions (61-98%) and maintaining stable disease or achieving a partial response at 6 months.[23] The observation of responses in non-irradiated lesions provided the first clinical evidence supporting the drug's ability to induce a systemic, immune-mediated abscopal effect.[23]
• LuPIN (Lutetium-PSMA + Idronoxil): This Phase I/II trial (ACTRN12618001073291) evaluated Veyonda® in combination with the targeted radionuclide therapy ¹⁷⁷Lutetium-PSMA-617 in a heavily pre-treated mCRPC population. The combination was proven to be safe and demonstrated impressive efficacy. A PSA decline of over 50% was observed in 61-62.5% of patients, and the median overall survival was 19.7 months—a highly encouraging outcome for patients who had exhausted most standard therapies.[42]

6.3.2 Refractory Solid Tumors: The Chemotherapy Enhancement Program (CEP)

The CEP-1 study (NCT02941523) was a Phase Ia/Ib trial designed to assess the safety and chemo-sensitizing potential of Veyonda®. The trial enrolled patients with various refractory solid tumors, including breast, lung, ovarian, and prostate cancer. Patients first received Veyonda® as a monotherapy to establish its safety, and then in combination with the chemotherapy agent carboplatin. The study successfully confirmed the favorable safety profile of the suppository formulation and provided encouraging signals of efficacy, with the majority of patients on the combination therapy achieving stable disease or better.[5]

6.3.3 Immuno-Oncology Combinations: The IONIC Trial

Building on the strong preclinical rationale for combining Idronoxil with immunotherapy, the Phase I IONIC trial (ACTRN12621001537842) is evaluating Veyonda® in combination with the PD-1 checkpoint inhibitor nivolumab. The trial is enrolling patients with a range of solid tumors. Preliminary results have been highly promising, with early signals of clinical response including stable disease, partial responses, and even complete responses. The combination appears to be well-tolerated. Crucially, analysis of peripheral blood mononuclear cells (PBMCs) from treated patients revealed a significant increase in the polyfunctionality of both effector CD4+ and CD8+ T-cells, providing direct clinical evidence that Veyonda® enhances the desired anti-tumor immune response in humans.[34]

6.3.4 Historical Trials in Ovarian and Other Cancers

Prior to the development of Veyonda®, earlier formulations of Idronoxil were tested in several clinical trials. A Phase II trial (NCT00557037) in prostate cancer was completed, and studies in platinum-resistant ovarian cancer showed promise for its use as a chemosensitizing agent.[13] A Phase I trial in mCRPC (NCT03041285) was terminated.[47] While these early trials provided important proof-of-concept for the drug's biological activity, their outcomes were ultimately constrained by the insurmountable pharmacokinetic limitations of the formulations used at the time.

6.4 Efficacy as a Chemo- and Radio-sensitizing Agent

A consistent and central theme throughout the entire development of Idronoxil is its potent ability to sensitize cancer cells to the cytotoxic effects of other therapies. Preclinical studies have demonstrated synergy with a wide range of standard chemotherapeutic agents, including platinum agents (cisplatin, carboplatin), taxanes (paclitaxel), anthracyclines (doxorubicin), and antimetabolites (gemcitabine, 5-fluorouracil, oxaliplatin).[9] This chemo-sensitizing effect, along with its demonstrated ability to enhance the effects of radiotherapy, forms a core part of its therapeutic value proposition, positioning it as an ideal combination partner to improve the efficacy of existing standard-of-care treatments.

Table 2: Summary of Major Clinical Trials Investigating Idronoxil/Veyonda®

Trial Name / Identifier	Phase	Indication(s)	Formulation	Intervention	Status	Key Reported Outcomes
DARRT-1 (NCT03307629)	1b	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Veyonda® (NOX66)	Veyonda® + Low-Dose Radiotherapy	Completed	Safe and well-tolerated; promising signals of durable efficacy; PSA response (61-98% reduction) and SD/PR at 6 months; evidence of abscopal effect.
LuPIN (ACTRN12618001073291)	1/2	mCRPC (heavily pre-treated)	Veyonda® (NOX66)	Veyonda® + ¹⁷⁷Lu-PSMA-617	Completed	Safe and effective; >50% PSA decline in 61-62.5% of patients; median Overall Survival of 19.7 months.
CEP-1 (NCT02941523)	1a/1b	Refractory Solid Tumors (Prostate, Lung, Breast, Ovarian, Head & Neck)	Veyonda® (NOX66)	Monotherapy & Combination with Carboplatin	Completed	Favorable safety profile; most patients achieved stable disease or better, demonstrating chemosensitizing potential.
IONIC (ACTRN12621001537842)	1	Solid Tumors	Veyonda® (NOX66)	Veyonda® + Nivolumab	Ongoing	Promising early signals of tumor response (SD, PR, CR); well-tolerated; increased polyfunctionality of CD4+ and CD8+ T-cells in patients.
NCT00557037	2	Prostate Cancer (Castrate & Non-Castrate)	Phenoxodiol (Oral)	Monotherapy	Completed	Established proof-of-concept for monotherapy activity but limited by formulation.
NCT03041285	1	mCRPC	Idronoxil (Suppository)	Idronoxil + Radiotherapy	Terminated	Early-phase trial that did not proceed.

7.0 Pharmacokinetics, Metabolism, and Formulation Science

The pharmacokinetic profile of Idronoxil is the central factor that has shaped its entire development history. Understanding the absorption, distribution, metabolism, and excretion (ADME) of the molecule is crucial to appreciating both its initial failure and its subsequent revitalization.

7.1 ADME Profile of Early Oral and Intravenous Formulations

Early clinical studies meticulously characterized the pharmacokinetics of Idronoxil using intravenous formulations. These studies provided clear evidence of the drug's metabolic instability.

• Following a single intravenous bolus injection in cancer patients, the plasma concentration of the active, unbound ("free") form of Idronoxil declined very rapidly, exhibiting an elimination half-life ($t_{1/2}$) of only 0.67 hours.[48]
• In contrast, the half-life of the "total" drug concentration (free drug plus its inactive metabolites) was significantly longer, at 3.19 hours.[48] This large discrepancy between the free and total drug half-lives is a classic pharmacokinetic signature of a compound that undergoes rapid and extensive metabolism into more stable, but inactive, forms.
• The total plasma clearance rate for the free drug was very high (2.48 L/h), further confirming its rapid removal from circulation.[48]
• During continuous intravenous infusion, steady-state plasma concentrations of the free drug were achieved in less than one hour, a direct consequence of its short half-life.[48]

7.2 The Role of Phase 2 Metabolism in Limiting Bioactivity

The key pharmacokinetic liability of Idronoxil is its high susceptibility to inactivation by Phase 2 metabolic enzymes.[5] These enzymes, which are highly concentrated in the liver, carry out conjugation reactions, such as glucuronidation. This process attaches a large, polar glucuronic acid molecule to the Idronoxil scaffold, which renders the drug pharmacologically inactive and highly water-soluble, facilitating its rapid excretion via the kidneys.

This efficient metabolic inactivation was the primary reason for the failure of early oral and intravenous formulations. When administered orally, the drug was subject to extensive first-pass metabolism in the liver before it could even reach systemic circulation. When administered intravenously, it was rapidly cleared from the blood by the same hepatic enzymes. In both cases, the result was an inability to maintain therapeutic concentrations of the active, free drug for a sufficient duration, which led to the discontinuation of its development.[1]

7.3 Anticipated Pharmacokinetics of the Veyonda® Formulation

The story of Idronoxil's pharmacokinetics is a powerful illustration of the critical role of formulation science in drug development. The molecule itself possesses potent biological activity, but it was rendered clinically ineffective by its ADME properties. The strategic pivot by Noxopharm to the Veyonda® rectal suppository formulation represents a classic drug delivery solution to a metabolic problem.

The Veyonda® formulation was specifically designed to leverage the anatomy of rectal venous drainage to bypass the first-pass effect in the liver.[5] By facilitating absorption directly into the systemic circulation, this formulation aims to significantly reduce the extent of initial Phase 2 metabolism. The explicit goal is to increase the bioavailability of the active, non-metabolized form of Idronoxil, resulting in higher peak plasma concentrations and a longer effective half-life.[5] While detailed pharmacokinetic data for the Veyonda® formulation are not available in the provided materials, the consistent positive safety and efficacy signals from the DARRT, LuPIN, and CEP clinical trials strongly imply that this formulation strategy has successfully achieved its objective of delivering therapeutically relevant concentrations of bioactive Idronoxil.

8.0 Safety, Tolerability, and Toxicology

A comprehensive assessment of Idronoxil's safety profile, drawing from preclinical toxicology studies and extensive clinical trial data across different formulations, is essential for evaluating its therapeutic index and potential for clinical use.

8.1 Preclinical Toxicology Assessment

Preclinical toxicology studies in animal models have generally indicated that Idronoxil is well-tolerated.[27] The observed low level of toxicity in these studies is mechanistically attributed to the drug's primary target, ENOX2, an enzyme whose expression is largely restricted to cancer cells. The relative lack of dependence of normal, non-tumor cells on ENOX2 activity is thought to provide a wide therapeutic window, accounting for the favorable safety profile seen in animals.[27] Standard chemical safety assessments, as detailed in the Material Safety Data Sheet (MSDS), classify the compound as harmful if swallowed (Acute Toxicity - Oral Category 4) and note that it is very toxic to aquatic life, mandating appropriate handling precautions in a laboratory or manufacturing setting.[51]

8.2 Clinical Safety Profile: An Analysis by Formulation and Indication

The clinical safety profile of Idronoxil has evolved significantly with its formulation.

• Early Intravenous Formulation: The adverse events associated with the early intravenous formulation were largely attributed not to Idronoxil itself, but to the cyclodextrin excipient required to solubilize the poorly water-soluble drug. These excipient-related toxicities included low-grade nausea, minor hypersensitivity reactions, and transient thrombocytopenia (low platelet count).[13]
• Early Oral Formulation: In a Phase I study of an oral formulation, the maximum tolerated dose (MTD) was determined to be 800 mg administered three times daily (t.i.d.). The dose-limiting toxicity at higher doses was mild diarrhea, which occurred in a small number of patients.[13]
• Veyonda® (NOX66) Rectal Suppository: The modern suppository formulation has demonstrated a consistently favorable safety profile across multiple clinical trials in late-stage cancer patients.[23]
• The most common adverse event directly related to the formulation is local perineal or anal irritation. This side effect is generally mild and readily managed with the application of topical corticosteroid creams.[34]
• When used in combination with other cancer therapies, the safety profile is manageable and largely reflects the known toxicities of the partner agents. In the DARRT trial (with radiotherapy), treatment-emergent adverse events (TEAEs) considered related to Veyonda® alone were mild (Grade 1), such as dry mouth and oral mucositis. No Grade 3 or higher TEAEs were attributed to Veyonda®.[23]
• In the CEP trial (with carboplatin), the overall safety profile was consistent with that expected for oncology patients receiving chemotherapy. The most common adverse events were hematological (blood and lymphatic system disorders), with only anemia being considered possibly related to Veyonda®.[45]

8.3 Synthesis of Adverse Events from Major Clinical Trials

Across the modern clinical programs using the Veyonda® formulation, the drug has been shown to be safe and well-tolerated. The majority of serious adverse events (SAEs) reported in these combination trials are attributable to the known toxicities of the partner therapies (radiotherapy, chemotherapy, radionuclide therapy) or to the progression of the underlying advanced cancer, rather than to Veyonda® itself.[23] While some patients have withdrawn from trials due to toxicity, this is an expected occurrence in studies involving heavily pre-treated, late-stage cancer populations with limited therapeutic options.[52] The overall safety data supports the continued clinical development of Veyonda® as a combination therapy.

Table 3: Consolidated Safety Profile and Common Adverse Events

Adverse Event	Early IV Formulation	Early Oral Formulation	Veyonda® + Radiotherapy (DARRT)	Veyonda® + Chemotherapy (CEP)	Veyonda® + ¹⁷⁷Lu-PSMA-617 (LuPIN)
Nausea	Low-grade (excipient-related)	Not prominent	Mild	Gastrointestinal disorders (16.7%)	Not prominent
Diarrhea	Not prominent	Mild (Dose-limiting at >800mg t.i.d.)	Not prominent	Gastrointestinal disorders (16.7%)	Not prominent
Hypersensitivity	Minor reactions (excipient-related)	Not reported	Not prominent	Not prominent	Not prominent
Thrombocytopenia	Transient (excipient-related)	Not prominent	Not prominent	Blood disorders (44.4%)	Anemia (common)
Anemia	Not prominent	Not prominent	Not prominent	Possibly related to NOX66 (44.4% blood disorders overall)	Common
Fatigue	Not prominent	Not prominent	Mild (related to both NOX66 and radiation)	Not prominent	Common
Perineal/Anal Irritation	N/A	N/A	Noted as manageable	Reported as manageable	Occurred in 38% (attributable to NOX66)
Dry Mouth / Mucositis	Not prominent	Not prominent	Mild (Grade 1)	Not prominent	Xerostomia (common)

Note: Frequencies and attributions are based on available data from sources.[13]

9.0 Regulatory Landscape and Commercial Strategy

The regulatory status and commercial strategy for Idronoxil are defined by its investigational nature and the central role of Noxopharm Ltd. in steering its modern development.

9.1 Global Regulatory Status: FDA, EMA, and TGA

Idronoxil, in any of its formulations including Veyonda®, is an investigational drug. It has not received marketing approval from any major global regulatory agency, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the Australian Therapeutic Goods Administration (TGA). Searches of EMA and TGA public databases do not indicate any current or past applications for marketing authorization.[53] The highest stage of clinical development reported for its various indications is Phase II or Phase I/II, confirming its status as a drug still under clinical investigation.[38]

9.2 Orphan Drug Designation for Soft Tissue Sarcoma

In a significant regulatory milestone, the U.S. FDA has granted Orphan Drug Designation to Veyonda® for the treatment of soft tissue sarcoma.[38] This designation is granted to drugs intended to treat rare diseases (affecting fewer than 200,000 people in the U.S.). It provides the sponsoring company with several key benefits, including tax credits for clinical trials, exemption from user fees, and, most importantly, the potential for seven years of market exclusivity upon approval. This designation serves as a powerful incentive to encourage the development of drugs for underserved patient populations.

9.3 The Role of Noxopharm in Revitalizing Idronoxil Development

Noxopharm Ltd., a clinical-stage Australian biotechnology company, is the sole entity driving the current clinical development of Idronoxil.[2] The company's corporate strategy was founded on the hypothesis that the potent anticancer activity of Idronoxil could be unlocked by solving its critical bioavailability problem. This led to the development of the proprietary Veyonda® (NOX66) suppository formulation.[2]

Noxopharm's strategy is a classic example of a biotech "value-inflection" approach. They identified a scientifically promising but commercially failed asset, diagnosed the specific reason for its failure (pharmacokinetics), and applied targeted innovation (formulation science) to de-risk the asset. Their subsequent clinical strategy is not a broad and costly push to market, but rather a series of smaller, highly targeted, and scientifically rational proof-of-concept combination trials (DARRT, LuPIN, IONIC, CEP). Each of these trials is designed to generate compelling data in a high-value oncology setting, such as late-stage prostate cancer or in combination with blockbuster immunotherapies.[15]

The company's stated commercial objective is not to become a fully integrated pharmaceutical company that markets its own drugs. Instead, the goal is to advance Veyonda® through Phase II clinical trials to generate a robust data package that demonstrates its safety and efficacy. This data package is intended to serve as a key asset in attracting a partnership, licensing deal, or outright acquisition by a major pharmaceutical company with the global resources to conduct large-scale Phase III trials and commercialize the drug.[35] Each successful trial serves as a critical "value inflection point," systematically increasing the value of the asset and making it a more attractive proposition for a potential partner.

10.0 Expert Synthesis and Future Outlook

A critical evaluation of the extensive body of evidence on Idronoxil reveals a drug with a unique profile and a compelling, albeit challenging, developmental history. Its future as a therapeutic agent depends on navigating the final stages of clinical validation and addressing key remaining questions.

10.1 Critical Appraisal of the Evidence: Strengths and Weaknesses

The therapeutic case for Idronoxil is built on several significant strengths, balanced by notable weaknesses and challenges.

Strengths:

• Multifaceted Mechanism of Action: Idronoxil's ability to attack cancer cells through multiple, synergistic pathways—including apoptosis induction, cell cycle arrest, topoisomerase II inhibition, and disruption of pro-survival signaling—provides a strong rationale for its potency and its ability to act as a sensitizer for other therapies.
• Novel Immuno-Oncology Function: The discovery of its ability to modulate the tumor immune microenvironment and potentially convert "cold" tumors to "hot" is a major strength, aligning it with the most promising and commercially significant area of modern oncology.
• Consistent Clinical Signals: Despite being from early-to-mid-stage trials, the clinical data for the Veyonda® formulation has shown consistent signals of meaningful activity and a favorable safety profile in heavily pre-treated, late-stage patient populations with high unmet needs.
• Strategic Formulation Solution: The successful development of the Veyonda® formulation to overcome the drug's primary pharmacokinetic flaw is a testament to sound pharmaceutical science and represents the key enabling factor for its current development.

Weaknesses:

• History of Failure: The previous discontinuation of the drug due to pharmacokinetic failure, while now addressed, may still create a perception of higher risk among potential partners and investors.
• Route of Administration: The reliance on a rectal suppository formulation, while scientifically sound, may present challenges in terms of patient acceptance, compliance, and commercial scalability compared to a more conventional oral or intravenous drug.
• Lack of Pivotal Data: The clinical evidence, while highly encouraging, is still derived from relatively small, non-randomized, Phase I/II studies. Definitive proof of efficacy will require successful completion of larger, randomized, controlled Phase III trials.

10.2 Key Unanswered Questions and Future Research Imperatives

To advance to the next stage of development and potential approval, several key questions must be addressed through future research:

• Definitive Pharmacokinetics of Veyonda®: While clinical outcomes imply success, detailed pharmacokinetic studies are needed to formally characterize the Cmax, Tmax, AUC, and half-life of bioactive Idronoxil delivered via the Veyonda® formulation in humans. This data is essential for optimizing dosing and for regulatory submissions.
• Pivotal Trial Validation: The promising efficacy signals from the DARRT, LuPIN, and IONIC trials must be validated in larger, randomized Phase III studies that compare the Veyonda®-containing combination regimens against the current standard of care.
• Optimal Dosing and Scheduling: Further studies are required to determine the optimal dose and schedule of Veyonda® when used in combination with a wide array of partners, including different chemotherapy agents, radiopharmaceuticals, and checkpoint inhibitors.
• Development of an Oral Formulation: The ultimate commercial potential of Idronoxil would be significantly enhanced by the development of a novel oral formulation that successfully overcomes the metabolic challenges. Research into formulation technologies such as nano-emulsions, solid lipid nanoparticles, or co-administration with metabolic inhibitors could be a high-value future endeavor.

10.3 Concluding Assessment of Idronoxil's Therapeutic Potential

In conclusion, Idronoxil, as revitalized in the Veyonda® formulation, stands as a highly promising investigational anticancer agent. Its unique pharmacological profile, combining direct oncotoxic effects with novel immuno-modulatory and sensitizing properties, positions it as an almost ideal "backbone" therapy for a new generation of combination treatments in oncology. The successful circumvention of its historical pharmacokinetic limitations has unlocked the potential of a potent and versatile molecule.

While significant clinical, regulatory, and commercial hurdles remain, the strength of the scientific rationale and the consistency of the clinical signals provide a solid foundation for its continued development. The future success of Idronoxil will ultimately depend on the rigorous execution of pivotal Phase III trials and its ability to demonstrate a clear and meaningful improvement in patient outcomes over the established standard of care. If it can achieve this, Idronoxil has the potential to become a valuable new tool in the treatment of a wide range of difficult-to-treat cancers, particularly in the high-value markets of metastatic prostate cancer and as a synergistic partner for immune checkpoint inhibitors.

Works cited

1. Idronoxil as an Anticancer Agent: Activity and Mechanisms - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/31899676/
2. APP Securities Company Research Report September 2016 - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/pdf/b892b352-cf78-4a3e-bb18-01107449b4c9/APP-Securities-Company-Research-Report-September-2016.pdf
3. Idronoxil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 23, 2025, https://go.drugbank.com/drugs/DB04915
4. Phenoxodiol | C15H12O3 | CID 219100 - PubChem, accessed October 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/219100
5. Study Details | NCT02941523 | Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours | ClinicalTrials.gov, accessed October 23, 2025, https://clinicaltrials.gov/study/NCT02941523?term=NCT00002854%20NCT00003597%20NCT00113438%20NCT00147225%20NCT00193583%20NCT00268905%20NCT00277069%20NCT00581971%20NCT00752011%20NCT00881166%20NCT00927589%20NCT01110603%20NCT01178112%20NCT01187199%20NCT01192165%20NCT01204996%20NCT01287520%20NCT01301716%20NCT01376310%20NCT01497470%20NCT01542047%20NCT01604863%20NCT01633970%20NCT01636622%20NCT01653470%20NCT01688791%20NCT02018861%20NCT02071537%20NCT02240017%20NCT02383212%20NCT02813135%20NCT02941523%20NCT03451331%20NCT03498521%20NCT03547973%20NCT05229497%20NCT05298592&rank=6
6. Idronoxil (Haginin E, Phenoxodiol, CAS Number: 81267-65-4) | Cayman Chemical, accessed October 23, 2025, https://www.caymanchem.com/product/30783/idronoxil
7. Phenoxodiol (Idronoxil) | Anticancer Agent | MedChemExpress, accessed October 23, 2025, https://www.medchemexpress.com/phenoxodiol.html
8. CAS 81267-65-4 Phenoxodiol - Alfa Chemistry, accessed October 23, 2025, https://www.alfa-chemistry.com/product/phenoxodiol-cas-81267-65-4-293776.html
9. Phenoxodiol sensitizes metastatic colorectal cancer cells to 5-fluorouracil- and oxaliplatin-induced apoptosis through intrinsic pathway - PMC, accessed October 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7355152/
10. Phenoxodiol: pharmacology and clinical experience in cancer ..., accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/19364253/
11. Phenoxodiol inhibits growth of metastatic prostate cancer cells - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/20564423/
12. Glycosylation of Semi-Synthetic Isoflavene Phenoxodiol with a Recombinant Glycosyltransferase from Micromonospora echinospora ATCC 27932 - PMC, accessed October 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9628886/
13. Idronoxil, accessed October 23, 2025, https://access.portico.org/Portico/show?viewFile=pdf&auId=pjbf78x8g9x
14. Phenoxodiol: isoflavone analog with antineoplastic activity - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/16507219/
15. Idronoxil Confirmed as New Immuno- Oncology Drug - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/PDF/1872_3/IdronoxilConfirmedasNewImmunoOncologyDrug
16. ASX: NOX - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/pdf/a50c1f5b-2269-4092-b244-d9c693358412/FNN-Interview-with-NOX-CEO-Explaining-IdronoxilC-Discovery.pdf
17. Idronoxil Confirmed as New Immuno- Oncology Drug - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/PDF/485d3133-1443-4130-9d63-773b2f357bba/IdronoxilConfirmedasNewImmunoOncologyDrug
18. Combination of Veyonda® + Radiotherapy Delivers Clinical Benefits - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/pdf/a50ba1e5-4522-46b6-902c-59e434caf1be/Veyonda-and-Radiotherapy-Delivers-Clinical-Benefits.pdf
19. IDRONOXIL - precisionFDA, accessed October 23, 2025, https://precision.fda.gov/ginas/app/ui/substances/001d9d12-9de8-4f8f-ab69-5c682b8d1be4
20. CNP0309500.0: Phenoxodiol - COCONUT database, accessed October 23, 2025, https://coconut.naturalproducts.net/compounds/CNP0309500.0
21. Idronoxil | Phenoxodiol | CAS#81267-65-4 | XIAP inhibitor | MedKoo ..., accessed October 23, 2025, https://www.medkoo.com/products/5746
22. Phenoxodiol | 81267-65-4 - ChemicalBook, accessed October 23, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5268269.htm
23. Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer. - ASCO Publications, accessed October 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.5533
24. DrugRepoBank, accessed October 23, 2025, https://awi.cuhk.edu.cn/DrugRepoBank/php/search_1_result_drugInfo.php?drug_name=219100
25. Definition of idronoxil - NCI Drug Dictionary - NCI, accessed October 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/idronoxil
26. pubchem.ncbi.nlm.nih.gov, accessed October 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/219100#:~:text=Idronoxil%20activates%20the%20mitochondrial%20caspase,resulting%20in%20tumor%20cell%20apoptosis.
27. Idronoxil Proapoptotic Agent Oncolytic - ResearchGate, accessed October 23, 2025, https://www.researchgate.net/publication/298949711_Idronoxil_Proapoptotic_Agent_Oncolytic
28. access.portico.org, accessed October 23, 2025, https://access.portico.org/Portico/show?viewFile=pdf&auId=pjbf78x8g9x#:~:text=Preclinical%20Pharmacology&text=Idronoxil%2Dinduced%20degradation%20of%20the,the%20extrinsic%20apoptot%2D%20ic%20pathway.
29. Phenoxodiol: pharmacology and clinical experience in cancer, accessed October 23, 2025, https://www.tandfonline.com/doi/abs/10.1517%2F14656560902837980
30. The effects of phenoxodiol on the cell cycle of prostate cancer cell lines - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/25400509/
31. Idronoxil Confirmed as Noxopharm's New Immuno-Oncology Drug - GlobeNewswire, accessed October 23, 2025, https://www.globenewswire.com/de/news-release/2019/04/16/1804706/0/en/Idronoxil-Confirmed-as-Noxopharm-s-New-Immuno-Oncology-Drug-Candidate.html
32. Independent Data Confirms Idronoxil Achieves Major Industry Goal of Converting 'COLD' Tumours to 'HOT' Tumours - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/pdf/434b717f-8550-4483-b483-b1772f898ab2/Data-Shows-Idronoxil-Holds-Key-to-Problem-of-COLD-Cancers.pdf
33. ASCO Abstract Confirms the Immunomodulatory Properties of Veyonda® - Noxopharm, accessed October 23, 2025, https://www.noxopharm.com/PDF/db8f570d-d926-4eca-b7fe-6866e3a9c921/VeyondaAbstractPublishedatASCOAnnualMeeting2022
34. A phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer. - ASCO Publications, accessed October 23, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e14591
35. Noxopharm Shareholder Update 2021 - Sydney, accessed October 23, 2025, https://www.noxopharm.com/PDF/dae9d74a-a127-40cb-9d41-04769962b199/NoxopharmShareholderUpdate2021
36. NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study - PubMed Central, accessed October 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8296080/
37. Cancer drug investigated as anti-inflammatory for lethal conditions including COVID-19 - Hudson Institute of Medical Research, accessed October 23, 2025, https://hudson.org.au/business-development-news/cancer-drug-investigated-as-anti-inflammatory-for-lethal-conditions-including-covid-19/
38. Kazia Therapeutics/Noxopharm - Idronoxil - AdisInsight - Springer, accessed October 23, 2025, https://adisinsight.springer.com/drugs/800049164
39. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/19535345/
40. Noxopharm Corporate Presentation September 2020, accessed October 23, 2025, https://www.noxopharm.com/pdf/337122aa-5b0f-4597-9718-d12456be6908/Noxopharm-Corporate-Presentation-September-2020.pdf
41. Noxopharm Annual Report Captures Continued Positive Progress, accessed October 23, 2025, https://www.noxopharm.com/pdf/391293f0-47eb-4bc8-9792-9f2eb97e09a0/Annual-Report-to-shareholders.pdf
42. New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients | Imaging Technology News, accessed October 23, 2025, https://www.itnonline.com/content/new-radionuclide-combination-therapy-safe-and-effective-metastatic-prostate-cancer-patients
43. Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial). - ASCO, accessed October 23, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT305493
44. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic ..., accessed October 23, 2025, https://jnm.snmjournals.org/content/63/4/560
45. NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study - PubMed, accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/34306271/
46. Idronoxil Completed Phase 2 Trials for Prostate Cancer Treatment ..., accessed October 23, 2025, https://go.drugbank.com/drugs/DB04915/clinical_trials?conditions=DBCOND0062462&phase=2&purpose=treatment&status=completed
47. Idronoxil Terminated Phase 1 Trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treatment | DrugBank Online, accessed October 23, 2025, https://go.drugbank.com/drugs/DB04915/clinical_trials?conditions=DBCOND0069854&phase=1&purpose=treatment&status=terminated
48. Pharmacokinetics of phenoxodiol, a novel isoflavone, following ..., accessed October 23, 2025, https://pubmed.ncbi.nlm.nih.gov/21291562/
49. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer - Griffith Research Online, accessed October 23, 2025, https://research-repository.griffith.edu.au/server/api/core/bitstreams/1327c4f6-8c89-5f80-93de-85f1b0e82a0c/content
50. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer - PMC - PubMed Central, accessed October 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3045896/
51. Safety Data Sheet - Cayman Chemical, accessed October 23, 2025, https://cdn.caymanchem.com/cdn/msds/30783m.pdf
52. FDA Grants Orphan Drug Designation to Veyonda for Patients With Soft Tissue Sarcoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways, accessed October 23, 2025, https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-veyonda-for-patients-with-soft-tissue-sarcoma
53. Medicines | European Medicines Agency (EMA), accessed October 23, 2025, https://www.ema.europa.eu/en/medicines
54. National registers of authorised medicines | European Medicines Agency (EMA), accessed October 23, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
55. Australian Register of Therapeutic Goods (ARTG), accessed October 23, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
56. accessed January 1, 1970, https://www.tga.gov.au/australian-register-therapeutic-goods
57. Noxopharm's hopes for a big pharma auction - Intelligent Investor, accessed October 23, 2025, https://www.intelligentinvestor.com.au/investment-news/noxopharms-hopes-for-a-big-pharma-auction/149484